GEN - Genetic Engineering and Biotechnology News

Precision Engineering Defines Next-Gen ADC

From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.
Business Insider

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu ® Clinical trial with AVA6103 is expected to be initiated ...
Contract Pharma

Engineering Commercial Success into the Next Generation of ADCs

Developers often treat payload selection, conjugation chemistry and commercial scale-up as isolated operations. This ...
Seeking Alpha

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data ...
London South East

PreCISION payload delivery advantage over ADC

LONDON and PHILADELPHIA - February 24, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology ...
Nasdaq

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...
Labroots

Mitigating ADC Toxicities With Linker-Payload Design

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Business Wire

Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications

MUNICH--(BUSINESS WIRE)--Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper describes the company ...
Seeking Alpha

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple ...

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...
Hosted on MSN

Synaffix and Qurient enter licensing deal for dual-payload ADC

Synaffix, a company of Swiss drugmaker Lonza, has entered into a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload antibody-drug conjugate (ADC). Synaffix ...
Business Wire

ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023

SEATTLE--(BUSINESS WIRE)--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the ...